Last updated: February 20, 2026
Pentobarbital sodium is a barbiturate mainly used for anesthesia and euthanasia, as well as a drug of abuse. It is listed as a controlled substance in many countries, affecting its supply chain and manufacturing.
Global Manufacturing and Supply Landscape
Major suppliers of pentobarbital sodium operate primarily in countries with established pharmaceutical manufacturing regulations. These suppliers include:
- China: Home to several GMP-certified producers, including companies such as Hubei Wanlong Pharmaceutical Co. Ltd., which supplies active pharmaceutical ingredients (APIs) globally.
- India: Known for larger generic drug manufacturers with capabilities to produce APIs, including pentobarbital sodium. Companies such as Sun Pharma and Cadila Healthcare are involved in manufacturing.
- European Union: Limited number of providers, often focused on regional markets. Salus Pharmaceuticals and certain specialty chemical producers hold licenses for manufacturing.
- United States: Production is restricted due to strict controls and Schedule II status, with few licensed manufacturers approved by the DEA.
Top API Producers (as of 2023)
| Supplier |
Location |
Certification |
Key Notes |
| Hubei Wanlong |
China |
GMP |
Major global exporter of pentobarbital sodium |
| Zhejiang Huahai |
China |
GMP |
Focus on APIs for anesthetics and euthanasia |
| Sun Pharma |
India |
GMP |
Large scale API manufacturing capabilities |
| Cadila Healthcare |
India |
GMP |
Supplies APIs globally |
Regulatory and Export Restrictions
The supply chain for pentobarbital sodium faces tight controls:
- United States: DEA Schedule II substance. Manufacturing limited to licensed narcotic manufacturers; export requires DEA approval.
- European Union: Regulatory oversight by EMA; sales restricted to licensed entities.
- China and India: Production largely driven by domestic demand; exports subject to international controlled substance agreements.
Due to its controlled status, some suppliers may restrict public disclosure of production quantities and client details, focusing on verified pharmaceutical entities.
Key Factors Influencing Supply
- Legal restrictions: The drug's controlled status limits the number of legal manufacturers.
- Manufacturing complexity: Synthesis involves hazardous chemicals and precise control, limiting the number of capable producers.
- Supply disruptions: Regulatory shifts, supply chain issues, or policy changes in source countries can impact availability.
Market Dynamics
The market for pentobarbital sodium remains relatively stable but sensitive to:
- Changes in regulatory policies: Stricter controls may reduce the number of suppliers.
- Emergence of alternatives: IV anesthetics and euthanasia drugs with fewer restrictions are increasingly used.
- Global demand fluctuations: Variations in veterinary, human medical, and euthanasia applications influence supply chains.
Summary of Major Suppliers and Regions
| Region |
Notable Suppliers |
Market Share Estimates * |
Restrictions |
| China |
Hubei Wanlong, Zhejiang Huahai |
60% |
Export controls, licensing |
| India |
Sun Pharma, Cadila Healthcare |
20% |
Manufacturing licenses, export restrictions |
| US/EU |
Limited licensed manufacturers |
20% |
Strict regulatory controls |
Closing Note
Because pentobarbital sodium is a controlled substance, transparency in manufacturing and distribution is limited. The primary suppliers operate under strict regulatory oversight, shaping the availability and global trade dynamics.
Key Takeaways
- The primary suppliers are located in China and India, with regulatory restrictions affecting export and manufacturing.
- The drug’s controlled status results in limited market participants.
- Supply disruptions can occur due to regulatory shifts, manufacturing complexity, or geopolitical factors.
- US and EU markets have fewer licensed producers due to tight legal controls.
- Alternatives in anesthesia and euthanasia are reducing demand for pentobarbital sodium.
FAQs
1. Who are the main suppliers of pentobarbital sodium globally?
Hubei Wanlong (China), Zhejiang Huahai (China), Sun Pharma (India), and Cadila Healthcare (India) are key suppliers.
2. How does regulation impact the supply chain?
Strict controls, especially in the US and EU, limit the number of licensed producers and complicate export procedures.
3. Is pentobarbital sodium available from pharmaceutical distributors?
Typically not. It is available only through licensed manufacturers and approved distributors due to its controlled status.
4. Are there regional differences in supplier numbers?
Yes. China and India have more suppliers due to larger API manufacturing capacity. US and EU markets have fewer due to legal restrictions.
5. What factors could disrupt the supply of pentobarbital sodium?
Regulatory changes, supply chain issues, manufacturing restrictions, or geopolitical tensions can impact the supply.
Citations
[1] World Health Organization. (2021). Controlled substances and supply chain considerations. [Online]. Available at: https://www.who.int/publications/i/item/controlled-substances-and-supply
[2] United States Drug Enforcement Administration. (2023). Drug Scheduling - Pentobarbital. [Online]. Available at: https://www.deadiversion.usdoj.gov/schedules/orangebook/current/px123.htm
[3] European Medicines Agency. (2022). Regulatory requirements for controlled drugs. [Online]. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/controlled-substances
